INO) will release its latest earnings report. Check out Benzinga’s preview to understand the implications.
Earnings and Revenue
Analysts covering Inovio Pharmaceuticals have modeled for quarterly EPS of $-0.17 on revenue of $2.61 million. In the same quarter last year, Inovio Pharmaceuticals announced EPS of $-0.3 on revenue of $135.67 thousand. If the company were to match the consensus estimate, earnings would be up 43.33%. Here’s how the company’s EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.22 | -0.24 | -0.26 | -0.27 |
| EPS Actual | -0.26 | -0.38 | -0.25 | -0.30 |
| Revenue Estimate | 1.91 M | 2.32 M | 3.93 M | 5.66 M |
| Revenue Actual | 1.33 M | 279.00 K | 866.86 K | 135.67 K |
Stock Performance
For a full 12 months, the return has risen by 756.04%. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
View more earnings on INO” data-reactid=”23″>View more earnings on INO
https://www.webcaster4.com/Webcast/Page/2021/36286” data-reactid=”24″>Don’t be surprised to see the stock move on comments made during its conference call. Inovio Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2021/36286
View Article Origin Here
